Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transient appearance of circulating tumor DNA associated with de novo treatment.

Scientific reports - 9 Dec 2016

Kato Kikuya, Uchida Junji, Kukita Yoji, Kumagai Toru, Nishino Kazumi, Inoue Takako, Kimura Madoka, Imamura Fumio

Abstract excerpt

The limitation of circulating tumor DNA (ctDNA) is its inability to detect cancer cell subpopulations with few or no dying cells. Lung cancer patients subjected to the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment were prospectively collected, and ctDNA levels represented by the activating and T790M mutations were measured. The first data set (21 patients) consisting of samples collected in the period from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Circulating Tumor DNA
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gene Library

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Radiotherapy

Source

Open in PubMed Open full text

Identifiers

PMID: 27934896
DOI: 10.1038/srep38639
PMCID: PMC5146655

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transient appearance of circulating tumor DNA associated with de novo treatment.PMID 27934896Read ↗

Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatmentSemantic proximity Read ↗

Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.Semantic proximity Read ↗

Analysis of the effect of baseline detection and early clearance of ct-DNA, on survival outcomes among patients with advanced EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Mixed ctDNA dynamics and decreased detection rates in early-stage lung cancer patients during radiation treatmentSemantic proximity Read ↗

Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.Semantic proximity Read ↗

Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients.Semantic proximity Read ↗

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment.Semantic proximity Read ↗

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Semantic proximity Read ↗

Clinical Implication of Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

A New Paradigm of the Origins of Circulating DNA in Patients with CancerSemantic proximity Read ↗

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.